

To: Mr. Matt Whitman
File: STN 125259/0 - Cervarix®
RE: Adverse Events and MPL
Date: July 10, 2007

APPROVED
An action letter developed at FDA on 8/14/07

We have the following comments pertaining to adverse events and the use of MPL-adjuvanted products.

CBER has been notified of an adverse event (transverse myelitis) which occurred in a subject who received a product adjuvanted with MPL. In the development of Cervarix®, a case of optic neuritis and a case of multiple sclerosis were reported in HPV-014, and a case of myelitis was reported for a subject who received (b)(4) product.

We request that you provide a meta-analysis of adverse events related to inflammatory neurological disorders (SAEs, unsolicited AEs) and also those adverse events of potentially autoimmune etiology that are non-neurological from all IND and non-IND studies which involve the use of MPL in humans from both GSK and Corixa sources. In addition, please provide a summary of all animal and in-vivo (human and animal) data that may reflect immunologically-based adverse reactions from both GSK and Corixa sources. For the clinical adverse event data, please use the same list of autoimmune diseases and presentation methods as in the Summary Report on Safety Data from Prophylactic Studies of GSK's AS04-containing (b)(4) and (b)(4) (submitted with the Cervarix® BLA). In addition, please include myelitis/transverse myelitis as one of the autoimmune adverse events. Also, in the above requested summary report, please group the SAEs by treatment group in tables that present all SAEs (e.g., Appendix Table 13, p. 94-111 and Appendix Table 31, p. 183-208).

Please submit these analyses to the Cervarix® BLA by the close of business August 27, 2007.

This request will also be sent by letter under IND (b)(4)